These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21083249)

  • 21. A placebo arm is not always necessary in clinical trials of amyotrophic lateral sclerosis.
    Gordon PH
    Muscle Nerve; 2009 Jun; 39(6):858-60. PubMed ID: 19382169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Standardization, more funds on horizon for clinical trials.
    McNeil C
    J Natl Cancer Inst; 2005 Apr; 97(8):555-7. PubMed ID: 15840874
    [No Abstract]   [Full Text] [Related]  

  • 23. Hemodynamic surrogate end-points in phase I studies?
    De Mey C
    Int J Clin Pharmacol Ther; 1997 Apr; 35(4):175-9. PubMed ID: 9112140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical development plan: N-Acetyl-l-cysteine.
    Kelloff GJ; Crowell JA; Boone CW; Steele VE; Lubet RA; Greenwald P; Alberts DS; Covey JM; Doody LA; Knapp GG
    J Cell Biochem Suppl; 1994; 20():63-73. PubMed ID: 7616754
    [No Abstract]   [Full Text] [Related]  

  • 25. New designs for phase II trials: application to a trial of targeted therapies vs. chemotherapy in patients age > 60 with AML/high-risk MDS.
    Estey EH
    Ann Hematol; 2004; 83 Suppl 1():S94-6. PubMed ID: 15124692
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluation of ventricular arrhythmias in early clinical pharmacology trials and potential consequences for later development.
    Min SS; Turner JR; Nada A; DiMino TL; Hynie I; Kleiman R; Kowey P; Krucoff MW; Mason JW; Phipps A; Newton-Cheh C; Pordy R; Strnadova C; Targum S; Uhl K; Finkle J
    Am Heart J; 2010 May; 159(5):716-29. PubMed ID: 20435178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tenth Annual Phase I Clinical Trials Conference. Improving risk management and safety and increasing efficiency in phase I clinical trials. 10-11 February 2009, London, UK.
    Morgan S
    IDrugs; 2009 Apr; 12(4):220-2. PubMed ID: 19350463
    [No Abstract]   [Full Text] [Related]  

  • 28. [Continual reassessment method (CRM)].
    Ishizuka N
    Gan To Kagaku Ryoho; 2000 Aug; 27(9):1449-57. PubMed ID: 10969605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo pharmacology in drug discovery and development.
    Svendsen O; Ahnfelt-Rønne I; Vanhoutte P
    Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):89-90. PubMed ID: 16918707
    [No Abstract]   [Full Text] [Related]  

  • 30. [Relatively good safety in Swedish phase I trials. A survey of studies reported to the Medical Products Agency during 3 years].
    Glazer A; Hedenmalm K
    Lakartidningen; 2008 Sep 10-16; 105(37):2482-4. PubMed ID: 19006863
    [No Abstract]   [Full Text] [Related]  

  • 31. Phase 1 clinical trials: not just for safety anymore?
    Khandekar J; Khandekar M
    Arch Intern Med; 2006 Jul; 166(14):1440-1. PubMed ID: 16864752
    [No Abstract]   [Full Text] [Related]  

  • 32. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
    LoRusso PM; Boerner SA; Seymour L
    Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early phase research and the process of scientific discovery.
    Schwartz GE
    J Altern Complement Med; 2007 May; 13(4):399. PubMed ID: 17532730
    [No Abstract]   [Full Text] [Related]  

  • 34. Subject's representative says researcher changed his report after problem arose.
    Maloney DM
    Hum Res Rep; 2001 Jun; 16(6):6-7. PubMed ID: 11785527
    [No Abstract]   [Full Text] [Related]  

  • 35. Drug development: from concept to marketing!
    Tamimi NA; Ellis P
    Nephron Clin Pract; 2009; 113(3):c125-31. PubMed ID: 19729922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. UK report recommends better planning for phase I drug trials.
    Mayor S
    BMJ; 2007 Mar; 334(7593):551. PubMed ID: 17363793
    [No Abstract]   [Full Text] [Related]  

  • 37. [Severe incidents in phase I clinical trial. How dangerous is the step from animal to man?].
    Löwer J
    MMW Fortschr Med; 2006 Apr; 148(15):20. PubMed ID: 16711197
    [No Abstract]   [Full Text] [Related]  

  • 38. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.
    Contrera JF; Matthews EJ; Kruhlak NL; Benz RD
    Regul Toxicol Pharmacol; 2004 Dec; 40(3):185-206. PubMed ID: 15546675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring and safety assessment in Phase I to III clinical trials.
    Fescharek R; Nicolay U; Arras-Reiter C
    Dev Biol Stand; 1998; 95():203-9. PubMed ID: 9855433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of anti-cancer drugs.
    Arrondeau J; Gan HK; Razak AR; Paoletti X; Le Tourneau C
    Discov Med; 2010 Oct; 10(53):355-62. PubMed ID: 21034677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.